Mounjaro – Talk Bio

Diabetes and Obesity Drug Boom to Propel Lilly and Novo Nordisk to Pharma Sales Leadership by 2030: Evaluate

1 week ago talkbio0Tagged CagriSema, Diabetes, eli lilly, Evaluate report, Mounjaro, Nordisk, Obesity, Ozempic, Pharmaceutical Sales, semaglutide, tirzepatide, top-selling drugs, Wegovy, Zepbound

diabetes; obesity; pharmaceutical sales; Eli Lilly; Novo Nordisk; Evaluate report; top-selling drugs; tirzepatide; semaglutide; Mounjaro; Zepbound; Ozempic; Wegovy; CagriSema; 2030 forecast

Compounders just lost their case to put obesity drug tirzepatide back in shortage

2 months ago talkbio0Tagged Drug Shortage, Eli, Eli Lilly, Facilities Association, Glucagon-Like Peptide 1, Legal Case, Mounjaro, OFA, tirzepatide, United States Food and Drug Administration, Zepbound

Tirzepatide, compounding, FDA, drug shortage, Eli Lilly, Zepbound, Mounjaro, legal case, Outsourcing Facilities Association (OFA), GLP-1 medications

Eli Lilly’s Zepbound Surpasses $4.9 Billion in First Year Sales Despite Q4 Shortfall

5 months ago talkbio0Tagged Advice, earnings, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Obesity, pharmaceutical revenue, Zepbound

Eli Lilly, Zepbound, obesity drug, Q4 2024 earnings, pharmaceutical revenue, GLP-1 medications, Mounjaro, 2025 guidance

Eli Lilly Intervenes in Lawsuit to Block Compounded Versions of Tirzepatide Following FDA’s Shortage Resolution

6 months ago talkbio0Tagged Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Pharmacy facility, shortage, United States Food and Drug Administration, Zepbound

Eli Lilly, tirzepatide, GLP-1 shortage, FDA, compounding pharmacies, lawsuit, Mounjaro, Zepbound

FDA Reaffirms End of Tirzepatide Shortage, Impacting Compounders

6 months ago talkbio0Tagged Compounders, Drug Shortage, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, United States Food and Drug Administration, Zepbound

FDA, tirzepatide, GLP-1, drug shortage, compounders, Eli Lilly, Mounjaro, Zepbound

EU Regulator Determines Mounjaro Effective for Sleep Apnea, No Separate Approval Required

7 months ago talkbio0Tagged EU, European Medicines Agency, Mounjaro, Obesity, Regulators (device)

Mounjaro, sleep apnea, EU regulator, European Medicines Agency (EMA), tirzepatide, weight loss, obesity

Limited Access to Mounjaro: England’s NHS Rolls Out Obesity Drug with Phased Approach

7 months ago talkbio0Tagged Access, England, Mounjaro, Nance-Horan syndrome, Obesity, Phase, rollout, Weight Loss Medication

Mounjaro, obesity drug, NHS England, limited access, phased rollout, weight loss medication, tirzepatide.

Lilly’s Obesity Drug Shortage Resolved, Novo’s Continues Amid Industry Efforts to Boost Manufacturing

9 months ago talkbio0Tagged Drug Shortage, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Nordisk, Obesity, pharmaceutical manufacturing, Wegovy, Weight-Loss Agents, Zepbound

Eli Lilly, obesity drug shortage, Mounjaro, Zepbound, Novo Nordisk, Wegovy, GLP-1 drugs, pharmaceutical manufacturing, weight loss drugs.

FDA Declares End to Tirzepatide Shortage, Impacting Compounded Versions of Mounjaro and Zepbound

9 months ago talkbio0Tagged Compound, Glucagon-Like Peptide 1, Mounjaro, tirzepatide shortage, United States Food and Drug Administration, Zepbound

tirzepatide shortage, FDA, Mounjaro, Zepbound, compounded medications, GLP-1 drugs

NHS England to Roll Out Eli Lilly’s Obesity Drug Mounjaro in Phased Approach

9 months ago talkbio0Tagged Eli, Eli Lilly, England, Mounjaro, Nance-Horan syndrome, Obesity, Phase, rollout, Weight Loss

NHS England, Eli Lilly, Mounjaro, Obesity Drug, Phased Rollout, Weight Loss, Tirzepatide